Analysis set: all treated||Total||32||Table 4:	Subject Disposition; All Treated Analysis Set (Study GEN501 Part 1)----Of the 32 subjects enrolled and treated, 15 subjects completed the study, receiving 7 full infusions of daratumumab.
Discontinued from treatment||<4 mg/kg||13 (65.0%)||Table 4:	Subject Disposition; All Treated Analysis Set (Study GEN501 Part 1)|||Discontinued from treatment||Total||17 (53.1%)||Table 4:	Subject Disposition; All Treated Analysis Set (Study GEN501 Part 1)----The remaining 17 (53%) discontinued treatment with daratumumab, 13 subjects (65%) in the <4 mg/kg group.
ECOG Score, n(%)|0||Total||14 (43.8%)||Table 5:	Demographics; All Treated Analysis Set (Study GEN501 Part 1)|||ECOG Score, n(%)|1||Total||17 (53.1%)||Table 5:	Demographics; All Treated Analysis Set (Study GEN501 Part 1)----Slightly more than half of the subjects (17; 53%) had a baseline ECOG performance score of Grade 1; 14 subjects (44%) had an ECOG performance score of Grade 0.
Any TEAE||Total||31 (96.9%)||Table 8:	Overview of Treatment-emergent Adverse Events; All Treated Analysis Set  (Study GEN501 Part 1)----In Part 1, 31 subjects (97%) experienced TEAEs.
Any serious TEAE|Drug-related||Total||5 (15.6%)||Table 8:	Overview of Treatment-emergent Adverse Events; All Treated Analysis Set  (Study GEN501 Part 1)----5 subjects (16%) having serious TEAEs related to study drug.
Total no. subjects with TEAEs||Total||31 (96.9%)||Table 9:	Most Common (at least 10%) Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set  (Study GEN501 Part 1)----In the All-Treated Part 1 population, 31 subjects (97%) experienced a TEAE.
MedDRA system organ class / Preferred term|General Disorders And Administration Site Conditions||Total||3 (9.4%)||Table 11:	Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set  (Study GEN501 Part 1)|||MedDRA system organ class / Preferred term|General Disorders And Administration Site Conditions|Pyrexia||Total||3 (9.4%)||Table 11:	Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set  (Study GEN501 Part 1)|||MedDRA system organ class / Preferred term|Infections And Infestations||Total||3 (9.4%)||Table 11:	Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set  (Study GEN501 Part 1)----In addition to the 2 cases of bronchospasm mentioned above, only pyrexia (3 subjects [9%], 1 each in the 2 mg/kg, 8 mg.kg, and 16 mg/kg dose groups) was reported in more than 1 subject (Table 11).
Analysis set: all treated||Total|Any Grade||32||Table 12:	Infusion Related Reactions by System Organ Class, Preferred Term and Toxicity Grade; All Treated Analysis Set  (Study GEN501 Part 1)  (8 mg/kg, 16 mg/kg, and Total)----Table 12 presents infusion-related reactions for subjects in the 8 mg/kg and 16 mg/kg treatment groups, as well as for the 32 subjects across all dose groups who are included in the All-Treated Part 1 population.
CL (mL/h/kg)|Mean||16 mg/kg N = 3||0.315||Table 18:	Summary of Daratumumab Pharmacokinetic Parameters for the First Full Infusion: Pharmacokinetic Analysis Set (Study GEN501 Part 1)|||CL (mL/h/kg)|Mean||16 mg/kg N = 3||0.104||Table 19:	Summary of Daratumumab Pharmacokinetic Parameters for the Last (7th) Full Infusion: Pharmacokinetic Analysis Set (Study GEN501 Part 1)----For the 16 mg/kg group, mean CL decreased from 0.315 mL/h/kg (n = 3) after the first full infusion to 0.104 mL/h/kg (n = 1) after the last full infusion.
CL (mL/h/kg)|Mean||24 mg/kg  N = 3||0.287||Table 18:	Summary of Daratumumab Pharmacokinetic Parameters for the First Full Infusion: Pharmacokinetic Analysis Set (Study GEN501 Part 1)|||CL (mL/h/kg)|Mean||2 mg/kg  N = 3||0.586||Table 19:	Summary of Daratumumab Pharmacokinetic Parameters for the Last (7th) Full Infusion: Pharmacokinetic Analysis Set (Study GEN501 Part 1)|||CL (mL/h/kg)|Mean||24 mg/kg  N = 3||0.162||Table 19:	Summary of Daratumumab Pharmacokinetic Parameters for the Last (7th) Full Infusion: Pharmacokinetic Analysis Set (Study GEN501 Part 1)----After the first full infusion, mean CL decreased from 1.06 mL/h/kg in the 2 mg/kg group to 0.287 mL/h/kg in the 24 mg/kg group; after the last (7th) full infusion, clearance decreased from 0.586 mL/h/kg (n = 1) in the 2 mg/kg group to 0.162 mL/h/kg (n = 2) in the 24 mg/kg group.
Analysis set: all treated||8 mg/kg - Cohort|Total||30||Table 21:	Subject Disposition - Treatment; All Treated Analysis Set (Study GEN501 Part 2)----All 30 subjects in the 8 mg/kg group discontinued treatment with daratumumab because of progressive disease (Table 21).
Race, n (%)|White||Total||47 (65.3%)||Table 22:	Demographics; All Treated Analysis Set (Study GEN501 Part 2)----The majority of subjects were white (47 subjects; 65%); median age was 61 years.
ECOG Score, n (%)|1||Total||51 (70.8%)||Table 22:	Demographics; All Treated Analysis Set (Study GEN501 Part 2)----Most subjects (51; 71%) had a baseline ECOG performance score of Grade 1.
Number of lines of prior therapy, n (%)|N|> 3 Lines||Total||50 (69.4%)||Table 23:	Baseline Disease Characteristics; All Treated Analysis Set (Study GEN501 Part 2)----The majority of subjects (50; 69%) received more than 3 lines of prior therapy.
Prior PI|Carfilzomib||16 mg/kg|Total||8 (19.0%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----All subjects (100%) received prior treatment with bortezomib and 8 subjects (19%) received prior treatment with carfilzomib.
Prior IMiD|Pomalidomide||16 mg/kg|Total||15 (35.7%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)|||Prior IMiD|Thalidomide||16 mg/kg|Total||19 (45.2%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----15 subjects (36%) received prior pomalidomide therapy; and 19 subjects (45%) received prior thalidomide therapy.
Prior IMiD|Thalidomide||8 mg/kg|Total||20 (66.7%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----20 subjects (67%) received prior thalidomide therapy.
Prior Allogeneic Stem Cell Transplant||8 mg/kg|Total||9 (30.0%)||Table 24:	Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----9 subjects (30%) had prior allogenic SCT.
Refractory toa|BORT+LEN+CARF+POM||16 mg/kg - Cohort||5 (11.9%)||Table 25:	Refractory Status to Prior Multiple Myeloma Therapy; All Treated Analysis Set (Study GEN501 Part 2)----Additionally,5 subjects (12%) were refractory to bortezomib+lenalidomide+carfilzomib+pomalidomide.
Analysis set: all treated||16 mg/kg||42||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)|||Duration of treatment (months)|Median||16 mg/kg||5.36||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)----Median duration of treatment for the 42 subjects in the 16 mg/kg group was 5.36 months.
Duration of treatment (months)|Range|≥ 1 - <3 months||8 mg/kg||12 (40.0%)||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)|||Duration of treatment (months)|Range|≥ 12 months||8 mg/kg||1 (3.3%)||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)----Most subjects (40%) were treated for 1 month or more, but less than 3 months; 1 subject (3%) was treated for 12 months or longer (Table 28).
Duration of treatment (months)|Range|≥ 12 months||16 mg/kg||3 (7.1%)||Table 28:	Daratumumab Infusions; All Treated Analysis Set (Study GEN501 Part 2)----3 subjects (7%) were treated for 12 months or longer (Table 28).
Analysis set: all treated||Total|Any||72||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)|||Total no. subjects with TEAEs||Total|Any||71 (98.6%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)----In the All-Treated Part 2 population, 71 subjects (71/72; 99%) experienced a TEAE.
MedDRA system organ class/Preferred term|Respiratory, thoracic and mediastinal disorders|Dyspnoea||8 mg/kg|Any Grade||8 (26.7%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)----In the 8 mg/kg group, most commonly reported TEAEs were upper respiratory tract infection (27%).
MedDRA system organ class/Preferred term|General disorders and administration site conditions||16 mg/kg|Grade 3 or 4||2 (4.8%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)|||MedDRA system organ class/Preferred term|Infections and infestations||16 mg/kg|Grade 3 or 4||2 (4.8%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)|||MedDRA system organ class/Preferred term|Blood and lymphatic system disorders|Neutropenia||16 mg/kg|Grade 3 or 4||2 (4.8%)||Table 30	Most Common (at least 10 %) Treatment-emergent Adverse Events by System Organ Class, Preferred Term and Grade 3/4 ; All Treated Analysis Set (Study GEN501 Part 2)----Attachment TSFAE02A summarizes the incidence of the most commonly reported TEAEs (at least 5% in any dose group) by SOC and preferred term.
MedDRA system organ class / Preferred term|Infections And Infestations|Pneumonia||Total||5 (6.9%)||Table 31:	Grade 3 or 4 Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)----Pneumonia (5 subjects; 7%) were the most common Grade 3/4 TEAEs.
MedDRA system organ class / Preferred term|Infections and infestations|Pneumonia||16 mg/kg||3 (7.1%)||Table 33:	Most Common (at least 1%) Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)|||MedDRA system organ class / Preferred term|Investigations|Crossmatch incompatible||16 mg/kg||3 (7.1%)||Table 33:	Most Common (at least 1%) Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)----In the 16 mg/kg group, the most common serious TEAEs were pneumonia (3 subjects; 7%).
MedDRA system organ class / Preferred term|Infections and infestations|Pneumonia||Total||6 (8.3%)||Table 33:	Most Common (at least 1%) Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)|||MedDRA system organ class / Preferred term|General disorders and administration site conditions|Pyrexia||Total||3 (4.2%)||Table 33:	Most Common (at least 1%) Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)|||MedDRA system organ class / Preferred term|Investigations|Crossmatch incompatible||Total||3 (4.2%)||Table 33:	Most Common (at least 1%) Serious Treatment-emergent Adverse Events by System Organ Class and Preferred Term; All Treated Analysis Set (Study GEN501 Part 2)----The most commonly reported serious TEAEs across both groups were pneumonia (6 subjects; 8%), pyrexia (3 subjects; 4%), and crossmatch incompatible (3 subjects; 4%).
Total number of subjects with event of infusion related reactions||8 mg/kg|Event Onset|2nd infusion||1 (5.0%)||Table 36:	Time to Onset of Infusion Related Reactions; All Treated Analysis Set (Study GEN501 Part 2)|||Total number of subjects with event of infusion related reactions||8 mg/kg|Event Onset|Subsequent infusions||2 (10.0%)||Table 36:	Time to Onset of Infusion Related Reactions; All Treated Analysis Set (Study GEN501 Part 2)----In the 8 mg/kg group, of 20 subjects with IRRs, all (100%) subjects had an IRR during the first infusion, 5% during the second infusion, and 10% during subsequent infusions.
Total number of subjects with event of infusion related reactions||Total|Total||51||Table 36:	Time to Onset of Infusion Related Reactions; All Treated Analysis Set (Study GEN501 Part 2)----Of the 51 subjects with IRRs across the combined 16 mg/kg and 8 mg/kg groups.
Analysis set: all treated||Total||72||Table 38:	Pre-Infusion Medications; All Treated Analysis Set (Study GEN501 Part 2)|||Antihistamines|Clemastine||Total||38 (52.8%)||Table 38:	Pre-Infusion Medications; All Treated Analysis Set (Study GEN501 Part 2)----All 72 subjects received analgesics (including analgesics used as antipyretics); antihistamines (most commonly clemastine [53%](Table 38).
Best response|Minimal response (MR)||8 mg/kg|n (%)||6 (20.0%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)|||----6 subjects (20%) have an MR.
Overall response (sCR+CR+VGPR+PR)||8 mg/kg|n (%)||3 (10.0%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----For subjects in the 8 mg/kg group, ORR was 10% (3 of 30 subjects; 95% CI: 2%; 27%).
Best response|Partial response (PR)||16 mg/kg - Cohort|Total|n (%)||11 (26.2%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----11 subjects (26%) achieved PRs.
Best response|Minimal response (MR)||16 mg/kg - Cohort|Total|n (%)||4 (9.5%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----4 subjects (10%) have an MR.
Best response|Stable disease (SD)||8 mg/kg|n (%)||14 (46.7%)||Table 45:	Overall Best Response based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----In addition, 14 subjects (47%) had stable disease.
Kaplan-Meier estimate|Median (95% CI)||8 mg/kg||6.9 (6.2, 10.6)||Table 47:	Duration of Response; Responders in All Treated Analysis Set (Study GEN501 Part 2)|||----For the 8 mg/kg group,the median duration of response for the 3 responders was 6.9 months (95% CI: 6.2,10.6).
Time to progression (months)|Number of events (%)||8 mg/kg||27 (90.0%)||Table 49:	Time to Disease Progression based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)|||Time to progression (months)|Number of events (%)||16 mg/kg||22 (52.4%)||Table 49:	Time to Disease Progression based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----Forty-nine TTP events were observed, 22 (52%) in the 16 mg/kg group and 27 (90%) in the 8 mg/kg group.
Kaplan-Meier estimate|Median (95% CI)||8 mg/kg||2.4 (1.4, 3.5)||Table 49:	Time to Disease Progression based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)|||Kaplan-Meier estimate|Median (95% CI)||16 mg/kg||5.6 (4.7, NE)||Table 49:	Time to Disease Progression based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----Median TTP for the 16 mg/kg group was 5.6 months (95% CI: 4.7, NE); median TTP for the 8 mg/kg group was 2.4 months (95% CI: 1.4, 3.5).
Progression-free survival (months)|Number of events (%)||8 mg/kg||27 (90.0%)||Table 50:	Progression-Free Survival based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)|||Progression-free survival (months)|Number of events (%)||16 mg/kg||23 (54.8%)||Table 50:	Progression-Free Survival based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----Fifty progression-free survival events (progressive disease or death) were observed, 23 (55%) in the 16 mg/kg group and 27 (90%) in the 8 mg/kg group.
Kaplan-Meier estimate|Median (95% CI)||8 mg/kg||2.4 (1.4, 3.5)||Table 50:	Progression-Free Survival based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)|||Kaplan-Meier estimate|Median (95% CI)||16 mg/kg||5.6 (4.2, 8.1)||Table 50:	Progression-Free Survival based on Computerized Algorithm; All Treated Analysis Set (Study GEN501 Part 2)----Median progression-free survival was 5.6 months (95% CI: 4.2, 8.1) for the 16 mg/kg group and 2.4 months (95% CI: 1.4, 3.5) for 8 mg/kg group.
Overall survival (months)|Number of events (%)||8 mg/kg||8 (26.7%)||Table 51:	Summary of Overall Survival; All Treated Analysis Set (Study GEN501 Part 2)|||Overall survival (months)|Number of events (%)||16 mg/kg||8 (19.0%)||Table 51:	Summary of Overall Survival; All Treated Analysis Set (Study GEN501 Part 2)----Sixteen events were observed, 8 (19%) in the 16 mg/kg group and 8 (27%) in the 8 mg/kg group.
Overall survival (months)|Number of censored (%)||8 mg/kg||22 (73.3%)||Table 51:	Summary of Overall Survival; All Treated Analysis Set (Study GEN501 Part 2)----22 events (73%) were censored in the 16 mg/kg.
Subjects with appropriate samplesa||8 mg/kg||27||Table 55:	Summary of Antibodies to Daratumumab; All Treated Analysis Set (Study GEN501 Part 2)|||Subjects with appropriate samplesa||16 mg/kg||39||Table 55:	Summary of Antibodies to Daratumumab; All Treated Analysis Set (Study GEN501 Part 2)|||Subjects with appropriate samplesa||Total||66||Table 55:	Summary of Antibodies to Daratumumab; All Treated Analysis Set (Study GEN501 Part 2)----None of the 66 subjects with antibody data tested positive for antibodies to daratumumab at any time point in Part 2 of the study (27 and 39 subjects for 8 and 16 mg/kg groups, respectively) (Table 55).
